Camelid immunoglobulins and nanobody technology

Area of Science:

• Immunology and Biotechnology
• Camelid antibody research
• Nanobody engineering

Background:

• Camelids possess unique heavy-chain antibodies (HCAbs) composed of heavy-chain homodimers, lacking light chains.
• These HCAbs utilize a single variable domain (VHH or nanobody) for antigen binding, offering distinct therapeutic and diagnostic potential.
• Conventional antibody purification and application face limitations that HCAbs can overcome due to their unique structure.

Purpose of the Study:

• To design a strategy for cloning and selecting dromedary nanobodies (Nbs) specific to target antigens.
• To explore the potential of these recombinant Nbs in various research, diagnostic, and therapeutic applications.
• To leverage the unique properties of HCAbs for novel biotechnological tools.

Main Methods:

• Immunization of dromedaries to elicit an immune response generating HCAbs.
• Cloning of the nanobody (Nb) repertoire from immunized dromedary serum.
• Selection of specific Nbs against target antigens and their production in bacteria.

Main Results:

• Monoclonal Nbs were successfully produced in bacteria, exhibiting high stability and solubility.
• Selected Nbs demonstrated high affinity and specificity for their cognate antigens.
• Recombinant Nbs were developed for diverse applications, including research probes, biosensors, diagnostics, and disease treatment.

Conclusions:

• Dromedary nanobodies (Nbs) are a versatile and powerful tool due to their unique structure and properties.
• Recombinant Nbs offer significant advantages for applications in diagnostics, biosensing, and therapeutics, including cancer and infectious diseases.
• The study validates a strategy for generating and utilizing HCAbs for biotechnological advancements.